470 related articles for article (PubMed ID: 25952770)
1. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
Wang F; Lou JF; Cao Y; Shi XH; Wang P; Xu J; Xie EF; Xu T; Sun RH; Rao JY; Huang PW; Pan SY; Wang H
Exp Mol Med; 2015 May; 47(5):e162. PubMed ID: 25952770
[TBL] [Abstract][Full Text] [Related]
2. Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy.
Cui EH; Li HJ; Hua F; Wang B; Mao W; Feng XR; Li JY; Wang X
Acta Pharmacol Sin; 2013 Feb; 34(2):309-13. PubMed ID: 22983388
[TBL] [Abstract][Full Text] [Related]
3. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
Sui C; Meng F; Li Y; Jiang Y
J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of serum microRNA-210 levels in nonsmall-cell lung cancer.
Li ZH; Zhang H; Yang ZG; Wen GQ; Cui YB; Shao GG
J Int Med Res; 2013 Oct; 41(5):1437-44. PubMed ID: 24065453
[TBL] [Abstract][Full Text] [Related]
5. Serum microRNA-365 in combination with its target gene TTF-1 as a non-invasive prognostic marker for non-small cell lung cancer.
Liu Y; Zhang G; Li H; Han L; Fu A; Zhang N; Zheng Y
Biomed Pharmacother; 2015 Oct; 75():185-90. PubMed ID: 26337230
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients.
Zhang J; Wang T; Zhang Y; Wang H; Wu Y; Liu K; Pei C
Cancer Biomark; 2018; 21(4):763-768. PubMed ID: 29286916
[TBL] [Abstract][Full Text] [Related]
7. Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer.
Guo W; Zhang Y; Zhang Y; Shi Y; Xi J; Fan H; Xu S
Int J Mol Med; 2015 Dec; 36(6):1720-6. PubMed ID: 26497897
[TBL] [Abstract][Full Text] [Related]
8. FATS expression is associated with cisplatin sensitivity in non small cell lung cancer.
Tian Y; Zhang J; Yan S; Qiu L; Li Z
Lung Cancer; 2012 Jun; 76(3):416-22. PubMed ID: 22137560
[TBL] [Abstract][Full Text] [Related]
9. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
[TBL] [Abstract][Full Text] [Related]
10. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
[TBL] [Abstract][Full Text] [Related]
11. Serum level of microRNA-147 as diagnostic biomarker in human non-small cell lung cancer.
Chu G; Zhang J; Chen X
J Drug Target; 2016 Aug; 24(7):613-7. PubMed ID: 26581116
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of microRNA-196a enhances the sensitivity of non-small cell lung cancer cells to cisplatin treatment.
Li Q; Yang Z; Chen M; Liu Y
Int J Mol Med; 2016 Apr; 37(4):1067-74. PubMed ID: 26936095
[TBL] [Abstract][Full Text] [Related]
13. Up-Regulation of miR-21 Expression Predicate Advanced Clinicopathological Features and Poor Prognosis in Patients with Non-Small Cell Lung Cancer.
Tian L; Shan W; Zhang Y; Lv X; Li X; Wei C
Pathol Oncol Res; 2016 Jan; 22(1):161-7. PubMed ID: 26453197
[TBL] [Abstract][Full Text] [Related]
14. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
15. MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.
Zhao H; Xie YZ; Xing R; Sun M; Chi F; Zeng YC
Cell Oncol (Dordr); 2017 Aug; 40(4):357-365. PubMed ID: 28567715
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of serum miR-25 in non-small-cell lung cancer.
Li J; Yu M; Liu Z; Liu B
Br J Biomed Sci; 2019 Jul; 76(3):111-116. PubMed ID: 30919763
[No Abstract] [Full Text] [Related]
17. Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer.
Xu L; Huang Y; Chen D; He J; Zhu W; Zhang Y; Liu X
Cancer Genet; 2014 May; 207(5):214-20. PubMed ID: 24906642
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Role of Circulating Exosomal miR-425-3p for the Response of NSCLC to Platinum-Based Chemotherapy.
Yuwen D; Ma Y; Wang D; Gao J; Li X; Xue W; Fan M; Xu Q; Shen Y; Shu Y
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):163-173. PubMed ID: 30228154
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-138 negatively regulates non-small cell lung cancer cells through the interaction with cyclin D3.
Han LP; Fu T; Lin Y; Miao JL; Jiang QF
Tumour Biol; 2016 Jan; 37(1):291-8. PubMed ID: 26201895
[TBL] [Abstract][Full Text] [Related]
20. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
Liu Q; Yu Z; Yuan S; Xie W; Li C; Hu Z; Xiang Y; Wu N; Wu L; Bai L; Li Y
Oncotarget; 2017 Feb; 8(8):13048-13058. PubMed ID: 28055956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
